DCF Advisers LLC Acquires 32,279 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Key Points

• DCF Advisers LLC increased its stake in Viridian Therapeutics by 108.5% in Q1, owning 62,029 shares valued at $836,000.
• In Q4, other institutional investors also significantly boosted their stakes in Viridian, with Price T Rowe Associates lifting theirs by over 2,800%.
• Despite a recent 0.6% decline, analysts maintain a "Moderate Buy" consensus rating for the stock with a price target averaging $37.00.

DCF Advisers LLC increased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 108.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,029 shares of the company's stock after buying an additional 32,279 shares during the quarter. DCF Advisers LLC owned 0.08% of Viridian Therapeutics worth $836,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. FMR LLC boosted its position in Viridian Therapeutics by 6.2% during the fourth quarter. FMR LLC now owns 11,881,912 shares of the company's stock worth $227,776,000 after purchasing an additional 698,434 shares during the period. Vanguard Group Inc. lifted its stake in shares of Viridian Therapeutics by 4.0% during the 4th quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock valued at $88,087,000 after buying an additional 174,952 shares in the last quarter. Deep Track Capital LP boosted its holdings in Viridian Therapeutics by 20.6% in the 4th quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock worth $86,701,000 after buying an additional 771,796 shares during the period. Tang Capital Management LLC boosted its holdings in shares of Viridian Therapeutics by 11.1% in the fourth quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company's stock worth $47,789,000 after acquiring an additional 250,000 shares during the period. Finally, Alliancebernstein L.P. grew its position in shares of Viridian Therapeutics by 3.8% in the fourth quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company's stock valued at $43,842,000 after purchasing an additional 84,255 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on VRDN. HC Wainwright reaffirmed a "buy" rating and set a $34.00 target price on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. JMP Securities lowered their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group reduced their price target on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Wells Fargo & Company dropped their target price on shares of Viridian Therapeutics from $27.00 to $26.00 and set an "equal weight" rating for the company in a report on Thursday. Finally, Royal Bank Of Canada decreased their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.13.

Viridian Therapeutics Stock Down 2.6%

Shares of NASDAQ VRDN traded down $0.45 during trading on Thursday, reaching $16.76. The company had a trading volume of 219,981 shares, compared to its average volume of 894,245. The stock has a market cap of $1.37 billion, a PE ratio of -4.34 and a beta of 0.42. The business's 50-day moving average is $15.84 and its 200 day moving average is $15.24. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The company has a quick ratio of 19.49, a current ratio of 19.49 and a debt-to-equity ratio of 0.05.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.00). Viridian Therapeutics had a negative return on equity of 70.61% and a negative net margin of 102,092.39%. The business had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.05 million. During the same period in the prior year, the firm posted ($0.81) EPS. The firm's quarterly revenue was up 4.2% on a year-over-year basis. As a group, equities analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.